Home › NCT07566975

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires

Exclusion Criteria:

* Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring / zero sensitivity

About the study

patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye

What is being tested

• Cyclosporine ophthalmic solution 0.1% (other)

Sponsor: Neuro-Ophthalmology of Texas · Participants: 50 · Started: Mar 31, 2026

Contact the study team

• Laura Perez · Phone: 12817238593
• Rosa A Tang, MD · Phone: 713-258-0009

Official record on ClinicalTrials.gov — NCT07566975

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.